Treatment of pre- and postmenopausal Women with HR+/HER2-metastatic Breast Cancer Ribociclib receives high AGO Recommendation Level

被引：0
|
作者：
Rudesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [1] Novartis' Ribociclib (Kisqali®) receives high AGO Level of Recommendation for endocrine Therapy in premenopausal Women with HER2-metastatic Breast Cancer
    不详
    BREAST CARE, 2021, 16 (03)
  • [2] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [3] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [4] Ribociclib (Kisqali®) from Novartis shows almost 5 Years of Overall Survival in pre- and perimenopausal Patients with HR+/ HER2-metastatic Breast Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (03)
  • [5] Metastatic HR+HER2-Breast Cancer Ribociclib also for endocrine Therapy in premenopausal Patients with high AGO Level of Recommendation
    Pommerl, Mascha
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 431 - 431
  • [6] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [7] Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib
    Balu, Sanjeev
    Burne, Rebecca
    Guerin, Annie
    Bungay, Rebecca
    Paul, Mary Lisha
    Sin, Roxana
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Ribociclib plus fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)
    Tolaney, S. M.
    Forero-Torres, A.
    Boni, V.
    Bachelot, T.
    Lu, Y-S
    Maur, M.
    Fasolo, A.
    Motta, M.
    Pan, C.
    Dobson, J.
    Hewes, B.
    Lee, S. Chin
    CANCER RESEARCH, 2017, 77
  • [9] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [10] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
12345